High Expression of TIMELESS Predicts Poor Prognosis: A Potential Therapeutic Target for Skin Cutaneous Melanoma

Shixin Zhao†, Shifeng Wen†, Hengdeng Liu†, Ziheng Zhou, Yiling Liu, Jinbao Zhong† and Julin Xie†

Background: Skin cutaneous melanoma (SKCM) is the most lethal skin cancer with an increasing incidence worldwide. The poor prognosis of SKCM urgently requires us to discover prognostic biomarkers for accurate therapy. As a regulator of DNA replication, TIMELESS (TIM) has been found to be highly expressed in various malignancies but rarely reported in SKCM. The objective of this study was to evaluate the relationship between TIM and SKCM tumorigenesis and prognosis.

Methods: We obtained RNA sequencing data from TCGA and GTEx to analyze TIM expression and differentially expressed genes (DEGs). Subsequently, GO/KEGG, GSEA, immune cell infiltration analysis, and protein-protein interaction (PPI) network were used to perform the functional enrichment analysis of TIM-related DEGs. Moreover, the receiver operating characteristic (ROC) curves, Cox regression analysis, Kaplan–Meier (K-M) analysis, and nomograms were applied to figure out the clinical significance of TIM in SKCM. In addition, we investigated the relationship between TIM promoter methylation and SKCM prognosis through the UALCAN database. Finally, the immunohistochemical (IHC) results of normal skin and SKCM were analyzed to determine expression differences.

Results: TIM was significantly elevated in various malignancies, including SKCM, and high expression of TIM was associated with poor prognosis. Moreover, a total of 402 DEGs were identified between the two distinct TIM expression groups, and functional annotation showed enrichment with positive regulation of cell cycle and classic oncogenic pathways in the high TIM expression phenotype, while keratinization pathways were negatively regulated and enriched. Further analysis showed that TIM was correlated with infiltration of multiple immune cells. Finally, IHC validated the differential expression of TIM in SKCM.

Conclusion: TIM might play a pivotal role in tumorigenesis of SKCM and is closely related to its prognosis.
INTRODUCTION

Skin cutaneous melanoma (SKCM) is the most lethal skin cancer with an increasing incidence worldwide, accounting for 287,723 new cases and 60,712 deaths in 2018 (1, 2). For patients with primary SKCM, complete resection is currently considered as the first choice, providing the highest probability of cure (3). However, there are quite limited means to treat patients with metastatic SKCM. Despite the significant progress in the adjuvant therapies of SKCM, many important questions remain, such as toxicity of chemotherapy, drug resistance, and expensive cost (3). Thus, increasing incidence worldwide, poor prognosis, and limited efficacy of available therapeutic tools prompted us to undertake extensive mechanistic investigations to discover novel prognostic biomarkers and new targets for therapy that might support precision medicine.

TIM, first identified in drosophila and subsequently in mammals, is not only involved in circadian rhythms, but also in cell cycle and DNA replication. Moreover, TIM also participate in cell survival after DNA damage or replication stress by promoting TIPIN nuclear localization and play an important role in epithelial cell morphogenesis (4). Anomalous cell cycle and molecular clockwork have been implicated in various diseases, notably tumorigenesis (5). Indeed, TIM has been demonstrated to be overexpressed in several malignancies compared to normal tissues, such as colorectal cancer, small cell lung cancer, and breast cancer (6–8). Not only that, the expression of TIM has been significantly associated with advanced tumor stages as well as poor prognosis (9). Therefore, TIM might has the potential to be used as a biomarker of cancer susceptibility, diagnosis, and prognostic outcome. Should this be the case, TIM could be a worthy therapeutic target.

In recent years, growing studies have shown that molecular factors (BRAF, MEK, PD-1) are important for biology, drug targeting, and prognosis in SKCM (10–12). To date, however, comprehensive studies of TIM in SKCM have yet to be reported. The focus of this study was to ascertain TIM expression level in SKCM and its potential prognostic significance. Moreover, the mechanisms by which TIM influences the prognosis of SKCM and its potential relationship to immune infiltration were also discussed.

MATERIALS AND METHODS

RNA-Sequencing Data and Ethics Statement

TPM expression values were downloaded from the UCSC XENA Project (https://xenabrowser.net/datapages/), which contains the TCGA and GTEX RNA-Seq data that was processed uniformly to provide more reliable expression analysis with tumor and normal samples (13, 14). Besides, clinicopathological information and corresponding RNA-seq data of SKCM in FPKM format were downloaded from the TCGA database (https://portal.gdc.cancer.gov/). Apart from 1 patient with incomplete clinicopathological information, a total of 471 SKCM patients were included. In this study, RNA-seq data was converted from FPKM to TPM format for further analysis. Since the UCSC XENA and TCGA database is publicly available in accordance with certain guidelines, it acknowledges that all written informed consents have been obtained before collecting data.

Differentially Expressed Genes (DEGs) in SKCM Tumors

According to the cut-off value of 50%, 471 SKCM patients were divided into low- and high-TIM expression groups. The “DESeq2” R package was used to identify DEGs between the two groups, where the log-fold change greater than 1.5 and adjusted P-value less than 0.05 were set as thresholds (15). The “ggplot2” R package was used to present the results in the form of volcano plots and heatmaps.

Functional Enrichment Analysis of TIM-Associated DEGs

The identified DEGs were then processed for functional enrichment analysis. The “clusterProfiler” and “ggplot2” R packages were used to analyze and visualize the functions of GO, including cell composition (CC), molecular function (MF), and biological process (BP), as well as KEGG pathway analysis (16).

Gene Set Enrichment Analysis (GSEA) of TIM-Associated DEGs

The “clusterProfiler” R package was utilized for the GSEA of DEGs to clarify the functional differences between the two subgroups (16). 1,000 permutations of the gene set were performed for each analysis. We selected C2: curated gene sets from MSigDB collections as reference gene sets. Clusters with adjusted p-value (p.adj) less than 0.05 and false discovery rate (FDR) less than 0.25 were identified as statistically significant (17). The “ggplot2” R package were used for GSEA visualization.

Relationship Between TIM and Immune Cell Infiltration in SKCM Tumors

The “GSVA” R package was utilized to analyze infiltration enrichment of 24 common immune cells, including activated dendritic cells (aDCs); B cells; CD8+ T cells; Cytotoxic cells; DCs; Eosinophils; immature DCs (iDCs); Macrophages; Mast cells; Neutrophils; NK CD56bright cells; NK CD56dim cells; NK cells; Plasmacytoid DCs (pDCs); T cells; T helper cells; T central memory (Tcm); T effector memory (Tem); T follicular helper (Tfh); T gamma delta (Tgd); Th1 cells; Th17 cells; Th2...
cells; Treg (18, 19). Subsequently, the spearman analysis was used to further verify the relationship between TIM expression and immune cell infiltration.

**Association of Clinicopathological Characteristics and TIM Expression in SKCM Patients**

The Wilcoxon rank sum test or Pearson’s chi-square test were used to compare the clinicopathological characteristics of the two distinct TIM groups. The overall survival (OS) was calculated from the date of diagnosis to the date of death or last follow-up. The disease specific survival (DSS) was calculated from the date of diagnosis to the date of death caused by SKCM. Univariate Cox proportional hazards regressions were utilized to identify the individual hazard ratio (HR) for the OS and DSS in SKCM patients. Subsequently, the significant variables in the univariate analysis \( (p < 0.05) \) were further subjected to multivariate analysis. The HR of individual factors was estimated by 95% confidence interval (CI).

**Clinical Significance of TIM Expression in SKCM**

In order to test the predictive accuracy of TIM for SKCM diagnosis, the “pROC” and “ggplot2” R packages were used to analyze and visualize ROC curves. Prognostic data of SKCM patients, including OS and DSS, was derived from a published study (20). The “survival” R package was used for statistical analysis of survival data, and the “survminer” R package was applied for visualization of K-M curves. Finally, the R package “rms” and “survival” were applied for generating nomograms and calibration plots (20).

**Promoter Methylation and Genetic Alterations of TIM in SKCM**

In order to determine if there is a relationship between TIM promoter methylation and tumor severity, we assessed the correlation between TIM promoter methylation status and cancer stages, nodal metastasis status in patients who enrolled in the UALCAN (http://ualcan.path.uab.edu/). Moreover, data and analysis of TIM mutation in SKCM were obtained from the cBioPortal database (http://www.cbioportal.org) and the images were also generated using the cBioPortal database. To further elucidate possible molecular mechanisms, we used STRING database (https://cn.string-db.org/) to construct protein-protein interaction (PPI) network and perform functional enrichment analysis.

**IHC Validation of TIM Expression**

To validate the results obtained in the bioinformatic prediction analysis, we collected IHC results of normal skin and SKCM tumors from the human pathology proteinatlas (HPA) database. 4 normal skin tissues and 14 SKCM tumors were collected. The integrated optical density (IOD) of each image and the corresponding stained area were measured using ImageJ 1.8.0 software. The mean optical density (MOD) was obtained by calculating the ratio, and the mean MOD (hereafter referred to as OD value) of three random fields was used to represent the expression level of TIM protein in SKCM and normal skin tissues.

**Statistical Analysis**

All statistical analysis and graphs were performed and visualized by R (3.6.3), and \( p \)-value less than 0.05 was considered as statistically significant.

**RESULTS**

**Expression Profiles of TIM in Pan-Cancers and Related Differentially Expressed Genes in SKCM**

Based on TCGA database, the expression of TIM mRNA in different cancers were determined. As shown in Figure 1A, among 33 cancer types, the TIM was significantly elevated in 25 cancers. More particularly, TIM expression was much higher in SKCM than in normal skin tissues \( (p < 0.001, \text{Figure 1B}) \). Interestingly, only two of the investigated cancer profiles was TIM expression decreased.

472 SKCM patients were stratified into two subgroups based on the median TIM expression. Next, we compared mRNA expression between the two groups. Finally, 402 mRNAs (146 upregulated and 256 downregulated, Figure 1C) were recognized as DEGs (absolute value of log₂FC > 1.5, \( p \)-adj < 0.05) between the two subgroups. Representative DEGs were also illustrated by heatmap (Figure 1D).

**Functional Annotation of TIM-Associated DEGs in SKCM**

In order to understand the functional implication of TIM-associated DEGs, GO and KEGG functional enrichment analysis was performed by clusterProfiler package (Supplementary Table S1 and Figure 2). The association with the biological process (BP) included keratinization, keratinocyte differentiation, and skin development; cellular components (CC) included cornified envelope, intermediate filament, and immunoglobulin complex; molecular function (MF) included structural constituent of epidermis, antigen binding, and peptidase inhibitor activity. KEGG included Ras signaling pathway, salivary secretion, and vascular smooth muscle contraction (Table 1).

To gain further insight into the biologic pathways involved in SKCM with different TIM expression levels, GSEA was performed to identify critical signaling pathways, which showed DEGs significantly enriched in cell proliferation related clusters (Figures 3A,B), including cell cycle control, and DNA replication. Besides, TIM-related DEGs were also associated with formation of cornified envelope (Figure 3C), and keratinization (Figure 3D). More importantly, DEGs were also enriched in cancer pathways (Figures 3E–I), such as TP53 activity, FOXM1 pathway, MYC activity, PLK1 pathway, and ATM pathway. These pathways (Supplementary Table S2) were observed in the enrichment of MSigDB Collection (C2.all.v7.0.symbols.gmt) and the criterion for significant difference was set at FDR < 0.05, \( p \)-adj < 0.05.
Association of TIM and Immune Cell Infiltration in SKCM

Spearman correlation analysis showed that the expression level of TIM in the SKCM microenvironment was correlated with the immune cell infiltration level quantified by ssGSEA. As shown in Figure 4A, Th2 cells, and T helper cells, were both positively correlated with TIM expression. However, pDC, TReg, NK CD56bright cells, and cytotoxic cells showed a negative association with TIM. More specifically, we evaluated the infiltration levels of six most relevant immune cells—Th2 cells (Figure 4B, R = 0.356, p < 0.001), T helper cells (Figure 4C, R = 0.180, p < 0.001), pDC (Figure 4D, R = −0.286, p < 0.001), TReg (Figure 4E, R = −0.197, p < 0.001), NK CD56bright (Figure 4F, R = −0.194, p < 0.001), and cytotoxic cells (Figure 4G, R = −0.190, p < 0.001)—in distinct TIM subgroups, which showed results consistent with those in Figure 4A.

Association of Clinicopathological Characteristics and TIM Expression in SKCM Patients

We examined the clinicopathological features of SKCM patients in the two distinct TIM expression subgroups. The main clinicopathological characteristics of SKCM patients were presented in Table 2. There was no significant difference in gender, age, body mass index (BMI), TNM stages, radiation therapy, ulceration, and Breslow depth between the two groups. However, there was a significant difference between the two subgroups in the composition of N stage, melanoma ulceration, melanoma Clark level, overall survival (OS) event, and disease specific survival (DSS) event.

Predictive Value of TIM for SKCM Diagnosis and Prognosis

Univariate and multivariate Cox proportional hazards analysis was performed to examine the clinical advantages of TIM. As shown in Tables 3, 4, the expression level of TIM is an independent risk factor for OS (HR = 1.724, p = 0.009) and DSS (HR = 1.593, p = 0.034). Subsequently, we used ROC curve to demonstrate its value on discriminating SKCM diagnosis. As the area under the curve (AUC) was 0.904, TIM showed significant high sensitivity and specificity for SKCM diagnosis (Figure 5A). Subsequently, K-M analyses were applied to verify the prediction of TIM on clinical outcomes. As shown in Figures 5B, C, OS (HR = 1.48, p = 0.005), and DSS (HR = 1.52, p = 0.005) in the high-TIM expression group would
were both statistically worse than those in the low-TIM expression group.

Moreover, to better predict the prognosis of SKCM patients, we constructed nomograms based on the results of multivariate Cox regression analysis. Four prognostic factors with statistical differences were included in the model, including clinical N stages, melanoma Clark level, Breslow depth, and TIM expression. As shown in Figures 5D,F, nomograms predicted OS and DSS at 1, 3, and 5 years, in which high expression of TIM predicted worse OS and DSS than low expression.
Additionally, we also constructed calibration plots to evaluate the prediction accuracy of two nomogram models. As shown in Figures 5E, G, the predicted results were highly consistent with actual survival outcomes, with the exception of the 5-year prediction for OS and DSS, which was slightly overestimated.

**Promoter Methylation and Genetic Alterations of TIM in SKCM**

To explore how TIM affects the prognosis of SKCM, we first explored the methylation levels and genetic mutations of TIM. Through the UALCAN database, we found that promoter methylation of TIM was lower in SKCM patients with both primary or metastatic tumors than in the normal group (Figure 6A). Moreover, the tumor stage and nodal metastasis status of SKCM also supported this conclusion (Figures 6B, C). Meanwhile, as shown in Figure 6D, TIM was altered in 6% of the queried SKCM patients. According to K-M analysis, patients with TIM alterations demonstrated shorter OS (Figure 6E).

Next, to further investigate the mechanisms behind TIM function, PPI network and GO/KEGG enrichment analysis was performed using STRING. Both PPI network and GO/KEGG pathways showed that TIM was related to DNA replication-related genes, including TOPBP1, WDHD1, TIPIN, CLSPN, and GINS3, and the cell cycle pathway (Figures 6F, G). These results indicated that TIM may regulate SKCM via regulating DNA replication and cell cycle.

**IHC Validation of TIM Expression**

To verify the former bioinformatic analysis results, we compared the gene expression of TIM in SKCM tissues vs normal skin controls using IHC data from the Human Protein Atlas (HPA) database. Representative images and analysis results were presented in Figure 7, the OD value of SKCM group was significantly higher than that of normal skin group ($p < 0.05$), consistent with the previous consequences.

**DISCUSSION**

In the present study, our results disclosed for the first time that TIM was overexpressed in SKCM tissues relative to normal tissues, which was also associated with poor prognosis. In addition, TIM-specific DEGs, primarily the up-regulated ones, were enriched in cell cycle, and several oncogenic signaling-related pathways. On the contrary, down-regulated DEGs were specifically enriched in keratinization. Subsequently, we assessed the relationship between the expression of TIM and immune infiltration. Besides, promoter methylation and genetic alterations of TIM in
regulating SKCM were also further elucidated. Finally, we uncovered the value of TIM in the diagnosis of SKCM and revealed that higher expression of TIM was associated with worse clinical outcomes, such as OS and DSS.

The genes controlling accurate DNA replication were essential for normal cell proliferation, as replication errors could lead to abnormal cell proliferation. TIM was a well-characterized DNA replication regulator, and emerging evidence suggested that it played an important role in various cancers (4). In this study, we found that TIM expression was significantly elevated in a variety of solid cancers, including esophageal carcinoma, head and neck squamous cell carcinoma, and lung squamous cell carcinoma. Furthermore, TIM was also upregulated in other tumor types, such as bladder urothelial carcinoma, breast invasive carcinoma, colon adenocarcinoma, brain lower grade glioma, rectum adenocarcinoma, and uterine carcinosarcoma. Therefore, TIM may act as a key hub gene in tumor genesis and development.

We then sought to identify the biological functions and mechanisms involving TIM in SKCM. TIM, as a classic molecular clockwork in mammals, has been shown not only to be a circadian regulator, but essential for early embryonic
The expression of TIM was associated with immune infiltration in the SKCM microenvironment. (A) Relationships among infiltration levels of 24 immune cell types and TIM expression profiles by Spearman's analysis. The comparison of infiltration levels of most correlated immune cells, including (B) Th2 cells, (C) T helper cells, (D) pDC, (E) TReg, (F) NK CD56bright cells, and (G) cytotoxic cells was shown.
development, DNA replication, and DNA damage repair (21–25). In this study, based on the functional annotation of TIM-associated DEGs, epidermal cell differentiation, keratinocyte differentiation, and skin development were closely related to TIM expression. In addition, according to the GSEA results, several cell cycle-related events and oncogenic related pathways were enriched in the high-TIM subgroup, while the downregulated DEGs were enriched in keratinization, and

### TABLE 2 | Association between TIM expression and clinicopathologic features in SKCM patients from the TCGA database.

| Characteristic         | levels              | TIM expression | p    | statistic |
|------------------------|--------------------|----------------|------|----------|
|                        | Low                | High           |      |          |
| T stage, n             | T1/T2/T3/T4       | 16/38/44/85    |      | 0.254    | x^2 = 4.07 |
| N stage, n             | N0/N1/N2/N3       | 100/50/25/25   |      | 0.002    | x^2 = 14.55 |
| M stage, n             | M0/M1             | 205/11         |      | 0.776    | x^2 = 0.08 |
| Pathologic stage, n    | Stage I/II/III/IV | 31/68/98/11    |      | 0.078    | x^2 = 6.82 |
| Radiation therapy, n   | No/Yes            | 196/34         |      | 0.167    | x^2 = 1.91 |
| Gender, n              | Female/Male       | 95/140         |      | 0.324    | x^2 = 0.97 |
| Age, n                 | ≤60/>60           | 134/97         |      | 0.147    | x^2 = 2.10 |
| BMI, n                 | ≤25/>25           | 45/82          |      | 0.593    | x^2 = 0.29 |
| Melanoma ulceration, n | No/Yes            | 60/91          |      | 0.021    | x^2 = 5.32 |
| Melanoma Clark level, n| I/II/III/IV/V    | 3/4/30/93/29   |      | 0.020    | x^2 = 11.66 |
| Breslow depth, n       | ≤3/>3             | 87/93          |      | 0.292    | x^2 = 1.11 |
| OS event, n (%)        | Alive/Dead        | 142/91         |      | 0.001    | x^2 = 10.57 |
| DSS event, n (%)       | Alive/Dead        | 152/79         |      | 0.001    | x^2 = 10.18 |

All bold values represent P values less than 0.05 to highlight statistical differences.

### TABLE 3 | Univariate and multivariate Cox proportional hazards analysis of TIM expression and OS for SKCM patients.

| Characteristics       | Univariate analysis | Multivariate analysis |
|-----------------------|---------------------|-----------------------|
|                       | Hazard ratio (95% CI) | p  | Hazard ratio (95% CI) | p  |
| T stage (T1&T2 vs. T3&T4) | 2.085 (1.501–2.895) | <0.001 | 0.890 (0.506–1.567) | 0.687 |
| N stage (N0 vs. N1&N2&N3) | 1.752 (1.304–2.354) | <0.001 | 4.844 (1.425–16.464) | 0.011 |
| M stage (M0 vs. M1)     | 1.897 (1.029–3.496) | 0.040 | 2.469 (0.935–6.520) | 0.068 |
| Age (≤60/>60)           | 1.656 (1.251–2.192) | <0.001 | 0.949 (0.625–1.440) | 0.806 |
| Gender (Female vs. Male)| 1.172 (0.879–1.563) | 0.281 |                   |     |
| Pathologic stage (I&II vs. III&IV) | 1.617 (1.207–2.165) | 0.001 | 0.436 (0.127–1.503) | 0.189 |
| Melanoma ulceration (No vs. Yes) | 2.085 (1.495–2.907) | <0.001 | 1.521 (0.998–2.316) | 0.051 |
| Melanoma Clark level (I&II&III vs. IV&V) | 2.167 (1.508–3.113) | <0.001 | 1.793 (1.077–2.986) | 0.025 |
| BMI (≤25 vs. >25)       | 0.827 (0.513–1.333) | 0.436 |                   |     |
| Breslow depth (≤3 vs. >3) | 2.651 (1.938–3.627) | <0.001 | 1.981 (1.169–3.357) | 0.011 |
| Radiation therapy (No vs. Yes) | 0.977 (0.694–1.377) | 0.895 |                   |     |
| TIM (Low vs. High)      | 1.480 (1.128–1.942) | 0.005 | 1.724 (1.144–2.600) | 0.009 |

All bold values represent P values less than 0.05 to highlight statistical differences.
formation of the cornified envelope. The above results indicated that TIM was not only a key regulator of DNA replication in SKCM, but also an inhibitor of keratinization. Several studies have confirmed that TIM knockdown suppressed cancer cell proliferation and clonogenic growth in colorectal cancer, lung cancer, breast and cervical cancer (8, 9, 26). Not only that, studies have verified that each melanocyte contacts with about 30 keratinocytes in the basal and suprabasal layers forming the epidermal-melanin unit (27, 28). The gap junctional intercellular communication (GJIC) formed by these two types of cells was essential for cell homeostasis. The inability to facilitate communication may be a reason for the poor prognosis of SKCM. More importantly, almost all tumorigenic-related pathways enriched in the high-TIM subgroup, including TP53, FOXM1, MYC, PLK1, and ATM signaling pathways, were related to regulating cell cycle, strongly suggesting the role of TIM to accelerate DNA replication and promote tumor cell proliferation, thereby worsening the prognosis of SKCM (30–33). Therefore, TIM expression might have important significance in SKCM tumorigenesis by regulating cell cycle and inhibiting keratinization.

In immune cell infiltration analysis, TIM expression was negatively correlated with pDC, TReg, NK CD56bright cells, Cytotoxic cells, and Th17 cells. Plasmacytoid dendritic cells (pDCs) is a subset of DCs denoted by their capacity to yield extensive amount of type I interferon (IFN-α) (34). In addition to IFN-α production, pDCs also serve as antigen-presenting cells (APCs) and regulate immune responses to various antigens. The significant role played by pDCs in regulating both the innate and adaptive components of the immune system makes them a critical player in cancer immunology. Cancers that can be detected clinically must have escaped anti-tumor immune responses to grow progressively (35). Therefore, pDCs, negatively related to TIM expression, may contribute to the immune escape of tumor cells in SKCM. In the subsequent immune response, NK cells and cytotoxic cells can cooperate to kill the tumor cells (36). Unfortunately, over-expression of TIM also caused a decrease in infiltrating cytotoxic cells and NK cells. On the other hand, we found a significant positive correlation between TIM expression and Th2 infiltrating. Although Th2 cells were best known for anti-parasites and allergic reactions, their regulation and function in the tumor microenvironment (TME) were highly controversial (37). However, emerging evidence showed that Th2 cells promoted cancer genesis, progression, and metastasis. Some studies showed that Th2 cells in the TME were related to the progression of breast cancer and cervical neoplasia (38, 39). Besides, Th2 cells had been shown to promote metastasis in breast cancer, colorectal cancer, and lung cancer (40–43). Hence, increased Th2 cell infiltration in the TME caused by TIM expression might have a role in SKCM tumorigenesis.
Another important issue was the clinical significance of TIM in SKCM. AUC of the ROC curve for TIM discrimination in SKCM diagnosis was 0.904, strongly suggesting that TIM was a reliable biomarker for SKCM diagnosis. Moreover, K-M survival analyses showed that patients with high TIM expression had a strikingly worse OS and DSS than patients...
with low TIM expression. Furthermore, the Cox analyses of this study demonstrated that TIM might be an independent predictive factor of poor prognosis for SKCM, in which N stage, melanoma Clark level, Breslow depth, and TIM expression were independent prognostic factors for OS and DSS deterioration. In addition, not only was the prognostic value of TIM confirmed in SKCM, but its expression level in a variety of tumors was negatively correlated with OS, such as papillary renal cell carcinoma (44), adrenocortical carcinoma (45), breast invasive carcinoma (46), and lung cancer (47). From the above results, it could be seen that TIM was highly expressed in these tumors and was often associated with poor

**FIGURE 6** Promoter methylation and genetic alterations of TIM and potential regulatory mechanism of TIM in regulating SKCM. (A–C) Relationship between tumor type, stage, and nodal metastasis status of SKCM with the promoter methylation of TIM determined using UALCAN. (D) Genetic alterations of TIM in SKCM patients determined using cBioportal. (E) OS for TIM alterations was analyzed using cBioportal. (F) The neighbor gene network of 20 genes was constructed using STRING. (G) The bar diagrams showed the top five terms for each GO category as well as for the KEGG pathway analysis. ***p < 0.001.
prognosis, which further confirmed that it was a common prognostic biomarker for multiple tumor types.

As for TIM gene alternative and DNA methylation, results of Fu et al. demonstrated that hypomethylation of TIM was associated with poorer prognosis and advanced stages of breast cancer (6). These results were consistent with later observations that higher TIM was related to shorter metastatic survival, especially in ER-positive/HER2-negative women (48). According to these results, it can be hypothesized that TIM overexpression might be the result of hypomethylation in the promoter region. In our study, analysis of UALCAN revealed that TIM gene promoter methylation was lower in both primary and metastatic SKCM compared to normal controls. Few studies have scrutinized the role of TIM mutations in SKCM. Among the surveyed SKCM patients, 6% had TIM mutations, which indicated a shorter OS. These findings suggested the promoter methylation and genetic alterations of TIM played an essential role in SKCM prognosis. Therefore, further research is needed in order to fully clarify the role of promoter methylation and genetic alterations in SKCM patients.

In order to further understand the biological functions of TIM, we constructed a PPI network using STRING database and conducted functional enrichment analysis on these genes. The results showed that the functions of these genes were mainly enriched in DNA replication and cell cycle, further supporting the above predicted results. Increased expression of TIM may affect the tumorigenesis and prognosis of SKCM by promoting the proliferation of melanoma cells.

The results of IHC indicated that the expression of TIM in SKCM tissues was higher than that in normal skin tissues, which was consistent with the previous prediction. Although we have disclosed the potential mechanism of TIM in SKCM tumorigenesis and its prognostic value in SKCM clinical outcomes, several factors could limit the extent to which the results can be generalized. First, as a potential novel therapeutic target, the sample size should be expanded in further research to enhance the reliability and representativeness of the results. Second, since we mainly focused on RNA-seq data from TCGA and GTEx databases, the results could be further verified by in vivo and in vitro research.

In conclusion, the highly expressed TIM in SKCM may play a pivotal role in tumorigenesis by regulating cell cycle and inhibiting melanocyte-keratinocyte GJIC. In addition, it also has prognostic value for clinical outcomes. Our results shed light on TIM as a potential therapeutic target for SKCM.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

ETHICS STATEMENT

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

SZ, SW, and HL contributed to the conception and design. JZ and JX contributed to the administrative support. ZZ and YL contributed to the provision of the study materials or patients. SZ, ZZ, and YL contributed to the collection and assembly of the data. SZ, SW, and HL contributed to the data analysis and interpretation. All the authors contributed to the writing and final approval of the manuscript.

FUNDING

National Natural Science Foundation of China (82072178, 81871566).
ACKNOWLEDGMENTS

We appreciate the precision medicine research platform of the First Affiliated Hospital of Sun Yat-sen University during the preparation of this manuscript.

REFERENCES

1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. (2019) 144:1941–53. doi: 10.1002/ijc.31937
2. Nikoulaus V, Stratigos AJ. Emerging trends in the epidemiology of melanoma. Br J Dermatol. (2014) 170:11–9. doi: 10.1111/bjd.12492
3. Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, et al. Guidelines for care of the management of primary cutaneous melanoma. J Am Acad Dermatol. (2019) 80:208–50. doi: 10.1016/j.jaad.2018.08.055
4. Mazzoccoli G, Laukkanen MÖ, Vinciguerra M, Colangelo T, Colantuoni V. A timeless link between circadian patterns and disease. Trends Mol Med. (2016) 22:68–81. doi: 10.1016/j.molmed.2015.11.007
5. Fu L, Lee CC. The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer. (2003) 3:350–10. doi: 10.1038/nrc1072
6. Fu A, Leaderer D, Zheng T, Hoffman AE, Stevens RG, Zhu Y. Genetic and epigenetic associations of circadian gene TIMELESS and breast cancer risk. Mol Carcinog. (2012) 51:923–9. doi: 10.1002/mc.20862
7. Mazzoccoli G, Vinciguerra M, Papa G, Piegoli A. Circadian clock circuitry in colorectal cancer. World J Gastroenterol. (2014) 20:4197–207. doi: 10.3748/wjg.v20.i15.4197
8. Yoshida K, Sato M, Hase T, Elshazley M, Yamashita R, Usami N, et al. TIMELESS is overexpressed in lung cancer and its expression correlates with poor patient survival. Cancer Sci. (2013) 104:171–7. doi: 10.1111/cas.12068
9. Mao Y, Fu A, Leaderer D, Zheng T, Chen K, Zhu Y. Potential cancer-related role of circadian gene TIMELESS suggested by expression profiling and in vitro assays. BMC Cancer. (2013) 13:498. doi: 10.1186/1471-2407-13-498
10. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe L, et al. Circadian gene TIMELESS suggested by expression profiling and in vitro assays. BMC Cancer. (2013) 13:498. doi: 10.1186/1471-2407-13-498
11. Danilova L, Wang H, Sunshine J, Kaunzit GJ, Cottrell TR, Xu H, et al. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proc Natl Acad Sci U S A. (2016) 113:E769–77. doi: 10.1073/pnas.1607811113
12. Guan J, Gupta R, Filipp FC. Cancer systems biology of TCGA SKCM: efficient detection of genomic drivers in melanoma. Sci Rep. (2015) 5:7857. doi: 10.1038/srep07857
13. Begk O, Lucas MC, Liu H, Ramírez JM, Mattick JS, Novoa EM. Integrative analyses of the RNA modification machinery reveal tissue- and cancer-specific signatures. Genome Biol. (2020) 21:97. doi: 10.1186/s13059-020-02009-2
14. Vivian J, Rao AA, Nothsta FA, Ketchum C, Armstrong J, Novak A, et al. Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol. (2017) 35:314–6. doi: 10.1038/nbt.3772
15. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. (2014) 15:550. doi: 10.1186/s13059-014-0055-0
16. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. (2012) 16:284–7. doi: 10.1089/omn.2011.0118
17. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. (2005) 102:15545–50. doi: 10.1073/pnas.0506580102
18. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. (2013) 39:782–95. doi: 10.1016/j.immuni.2013.10.003
19. Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. (2013) 14:17. doi: 10.1186/1471-2105-14-17
20. Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Azar AJ, Cherniack AD, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. (2018) 173:400–16.e11. doi: 10.1016/j.cell.2018.02.052
21. Engelen E, Janssens RC, Yagita K, Smits VA, van der Horst GT, Tamanini F. Mammalian TIMELESS is involved in period determination and DNA damage-dependent phase advancing of the circadian clock. PLoS One. (2013) 8:e6623. doi: 10.1371/journal.pone.006623
22. Murakami H, Keeny S. Temporospatial coordination of mitotic DNA replication and recombination via DDK recruitment to replisomes. Cell. (2014) 158:861–73. doi: 10.1016/j.cell.2014.06.028
23. O’Reilly LP, Zhang X, Smithgall TE. Individual Src-family tyrosine kinases direct the degradation or protection of the clock protein Timeless via differential ubiquitination. Cell. Signal. (2013) 25:860–6. doi: 10.1016/j.cellsig.2012.12.009
24. Gotter AL, Manganaro T, Weaver DR, Kolakowski Jr LF, Possidente B, Sridam S, et al. A time-less function for mouse timeless. Trends Mol Med. (2014) 20:550. doi: 10.1016/j.molmed.2014.01.002
25. Scatolini M, Patel A, Grosso E, Mello-Grand M, Ostano P, Coppo R, et al. GJB5 association with BRAF mutation and survival in cutaneous malignant melanoma. Br J Dermatol. (2012) 167:116–28. doi: 10.1111/bjd.20629
26. Baluapuri A, Wolf E, Eilers M. Target gene-independent functions of MYC oncoproteins. Nat Rev Mol Cell Biol. (2020) 21:255–67. doi: 10.1038/s41580-020-0215-2
27. Tan BC, Liu H, Lin CL, Lee SC. Functional cooperation between FACT and MCM is coordinated with cell cycle and differential complex formation. J Biomed Sci. (2010) 17:11. doi: 10.1186/1423-0127-11-11
28. Fischer M, Grossmann P, Padi M, DeCaprio JA. Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F target gene analyses identify cell cycle gene regulatory networks. Nucleic Acids Res. (2016) 44:66070–86. doi: 10.11997/gw1k/gw253
29. Raab CA, Raab M, Becker S, Streberhardt K. Non-mitotic functions of pole-like kinases in cancer cells. Biochim Biophys Acta Rev Cancer. (2021) 1875:188467. doi: 10.1016/j.bbcan.2020.188467
30. Jegougorac NJ, Young HA, Amrutre SB, Olshasky SL, Fitzgerald-Bocarsly P. Virally stimulated plasmacytoid dendritic cells produce chemokines and induce migration of T and NK cells. J Leukoc Biol. (2004) 75:504–14. doi: 10.1189/jlb.0603291
31. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. (2020) 21:97. doi: 10.1186/s13059-020-0124-2

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fsurg.2022.917776/full#supplementary-material.
36. Giese MA, Hind LE, Huttenlocher A. Neutrophil plasticity in the tumor microenvironment. Blood. (2019) 133:2159–67. doi: 10.1182/blood-2018-11-844548
37. Schreiber S, Hammers CM, Kaesch AJ, Schraven B, Dudeck A, Kahlffuss S. Metabolic interdependency of Th2 cell-mediated type 2 immunity and the tumor microenvironment. Front Immunol. (2021) 12:632581. doi: 10.3389/fimmu.2021.632581
38. Feng Q, Wei H, Morihara J, Stern J, Yu M, Kiviat N, et al. Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma. Gynecol Oncol. (2012) 127:412–9. doi: 10.1016/j.ygyno.2012.07.098
39. Espinoza JA, Jabeen S, Batra R, Papaleo E, Haakensen V, Timmermans Wielenga V, et al. Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics. Oncoimmunology. (2016) 5:e1248015. doi: 10.1080/2162402x.2016.1248015
40. Zhang Q, Qin J, Zhong L, Gong L, Zhang B, Zhang Y, et al. CCL5-mediated Th2 immune polarization promotes metastasis in luminal breast cancer. Cancer Res. (2015) 13:5472-21. doi: 10.1158/0008-5472.Can-14-3590
41. Zaynagetdinov R, Sherrill TP, Gleaves LA, McLoed AG, Saxon JA, Habermann AC, et al. Interleukin-5 facilitates lung metastasis by modulating the immune microenvironment. Cancer Res. (2015) 75:1624–34. doi: 10.1158/0008-5472.Can-14-2379
42. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. (2009) 16:91–102. doi: 10.1016/j.ccr.2009.06.018
43. Chen J, Gong C, Mao H, Li Z, Fang Z, Chen Q, et al. E2F1/SP3/STAT6 axis is required for IL-4-induced epithelial-mesenchymal transition of colorectal cancer cells. Int J Oncol. (2018) 53:567–78. doi: 10.3892/ijo.2018.4429
44. Xia S, Lin Y, Lin J, Li X, Tan X, Huang Z. Increased expression of TICRR predicts poor clinical outcomes: a potential therapeutic target for papillary renal cell carcinoma. Front Genet. (2020) 11:605378. doi: 10.3389/fgene.2020.605378
45. Xie L, Wang Q, Nan F, Ge L, Dang Y, Sun X, et al. OSacc: gene expression-based survival analysis web tool for adrenocortical carcinoma. Cancer Manag Res. (2019) 11:9145–52. doi: 10.2147/cmar.S215586
46. Yan Z, Wang Q, Sun X, Ban B, Lu Z, Dang Y, et al. OSbrca: a web server for breast cancer prognostic biomarker investigation with massive data from tens of cohorts. Front Oncol. (2019) 9:1349. doi: 10.3389/fonc.2019.01349
47. Yan Z, Wang Q, Lu Z, Sun X, Song P, Dang Y, et al. OSluca: an interactive web server to evaluate prognostic biomarkers for lung cancer. Front Genet. (2020) 11:420. doi: 10.3389/fgene.2020.00420
48. Cadenas C, van de Sandt L, Edlund K, Lohr M, Hellwig B, Marchan R, et al. Loss of circadian clock gene expression is associated with tumor progression in breast cancer. Cell Cycle. (2014) 13:3282–91. doi: 10.4161/15384101.2014.954454

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zhao, Wen, Liu, Zhou, Liu, Zhong and Xie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.